As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the semiconductor manufacturing industry, including Applied Materials (NASDAQ:AMAT) and its peers.
ZoomInfo trades at $9.21 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 5.2% while the S&P 500 is down 3.5%. This might have investors contemplating their next move.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at vehicle retailer stocks, starting with CarMax (NYSE:KMX).
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Beer (NYSE:SAM) and the best and worst performers in the beverages, alcohol, and tobacco industry.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Tyson Foods (NYSE:TSN) and the best and worst performers in the perishable food industry.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the gaming solutions stocks, including Light & Wonder (NASDAQ:LNW) and its peers.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Alignment Healthcare (NASDAQ:ALHC) and the rest of the health insurance providers stocks fared in Q4.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Grand Canyon Education (NASDAQ:LOPE) and the rest of the education services stocks fared in Q4.
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
